Hepatology International最新文献

筛选
英文 中文
Letter regarding the ANCHOR trial: methodological perspectives on GM-CSF efficacy and HBsAg prediction. 关于ANCHOR试验的信函:GM-CSF疗效和HBsAg预测的方法学观点。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-01 Epub Date: 2026-03-03 DOI: 10.1007/s12072-025-11032-w
Xiaolong Lu, Meng Li, Ximeng Ren, Yao Song, Shuangshuang Liu, Yang Liu
{"title":"Letter regarding the ANCHOR trial: methodological perspectives on GM-CSF efficacy and HBsAg prediction.","authors":"Xiaolong Lu, Meng Li, Ximeng Ren, Yao Song, Shuangshuang Liu, Yang Liu","doi":"10.1007/s12072-025-11032-w","DOIUrl":"10.1007/s12072-025-11032-w","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1255-1256"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147348256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
APASL_2026_Istanbul. APASL_2026_Istanbul。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-01 DOI: 10.1007/s12072-026-11095-3
{"title":"APASL_2026_Istanbul.","authors":"","doi":"10.1007/s12072-026-11095-3","DOIUrl":"10.1007/s12072-026-11095-3","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1-806"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148701208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to letter to the editor "Diagnostic criteria for fatty liver disease: lessons from other diseases". 对致编辑的信“脂肪肝的诊断标准:来自其他疾病的经验教训”的回复。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-01 Epub Date: 2026-02-05 DOI: 10.1007/s12072-026-11047-x
Yun Kyung Cho, Chang Hee Jung
{"title":"Response to letter to the editor \"Diagnostic criteria for fatty liver disease: lessons from other diseases\".","authors":"Yun Kyung Cho, Chang Hee Jung","doi":"10.1007/s12072-026-11047-x","DOIUrl":"10.1007/s12072-026-11047-x","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1262-1263"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical clustering identifies MASLD subtypes with distinct longitudinal cardiovascular risks and lipidomic profiles. 临床聚类确定MASLD亚型具有不同的纵向心血管风险和脂质组学特征。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-01 Epub Date: 2026-05-26 DOI: 10.1007/s12072-026-11103-6
Zhixin Tu, Yu Ding, Tong Yue, Hongqiang Zhang, Ting Peng, Pingting Yang, Weiwei Qin, Jiangang Wang, Jianping Weng, Sihui Luo
{"title":"Clinical clustering identifies MASLD subtypes with distinct longitudinal cardiovascular risks and lipidomic profiles.","authors":"Zhixin Tu, Yu Ding, Tong Yue, Hongqiang Zhang, Ting Peng, Pingting Yang, Weiwei Qin, Jiangang Wang, Jianping Weng, Sihui Luo","doi":"10.1007/s12072-026-11103-6","DOIUrl":"10.1007/s12072-026-11103-6","url":null,"abstract":"<p><strong>Background and aims: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits substantial heterogeneity in progression and cardiovascular outcomes. We aimed to identify reproducible MASLD subtypes in Chinese cohorts, characterize their distinct lipidomic profiles, and evaluate their associations with long-term cardiovascular outcomes.</p><p><strong>Methods: </strong>We investigated the heterogeneity of MASLD using k-means clustering based on six simple clinical variables in a cohort of 5,329 individuals. The identified clusters were applied in an independent cohort of 1,432 participants. Cardiovascular outcomes were compared across clusters using Kaplan-Meier curves and log-rank tests. Untargeted lipidomic profiling was performed with partial least squares discriminant analysis and least absolute shrinkage and selection operator regression to identify discriminative lipids for XGBoost model. Feature importance was evaluated using SHapley Additive exPlanations.</p><p><strong>Results: </strong>Three distinct MASLD subtypes were identified. Cluster A (Metabolic-Obesity subtype), characterized by the highest BMI and triglycerides with the lowest risk of cardiovascular outcomes. Cluster B (Dysglycemic subtype) distinguished by increased glycated hemoglobin. Cluster C (Aging-Hypertensive subtype) was primarily associated with age, blood pressure, and fibrosis markers, leading to higher risk of cardiovascular outcomes. Lipidomics identified 1061 metabolites, and ten lipids distinguishing the Cluster A and C were selected for modeling, yielding an area under the receiver operating characteristic curve of 0.900. Pathway enrichment analysis further revealed the Cluster C involved in sphingolipid metabolism.</p><p><strong>Conclusions: </strong>Three distinct MASLD subtypes with varying metabolic features and cardiovascular risks were identified in Chinese cohorts. The Aging-Hypertensive subtype showed the highest cardiovascular risk and was associated with dysregulated sphingolipid metabolism. These findings underscore the clinical heterogeneity of MASLD and highlight the need for risk classification and personalized intervention strategies.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1047-1057"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148029667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spatial analysis identifies LAMTOR2 overexpression in hepatocellular carcinoma with vessels encapsulating tumor clusters. 空间分析发现LAMTOR2在血管包裹肿瘤簇的肝细胞癌中过表达。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-01 Epub Date: 2026-06-25 DOI: 10.1007/s12072-026-11115-2
Yoon Jung Hwang, San Ha Hwang, Min Ji Kang, Geon Woo Park, Hyeewon Seo, Hyejung Lee, Hyun Je Kim, Suk Kyun Hong, Haeryoung Kim
{"title":"Spatial analysis identifies LAMTOR2 overexpression in hepatocellular carcinoma with vessels encapsulating tumor clusters.","authors":"Yoon Jung Hwang, San Ha Hwang, Min Ji Kang, Geon Woo Park, Hyeewon Seo, Hyejung Lee, Hyun Je Kim, Suk Kyun Hong, Haeryoung Kim","doi":"10.1007/s12072-026-11115-2","DOIUrl":"10.1007/s12072-026-11115-2","url":null,"abstract":"<p><strong>Background: </strong>Vessels encapsulating tumor clusters (VETC) is a distinct angiogenic pattern in hepatocellular carcinoma (HCC). While VETC-positive HCC is associated with poor prognosis, it demonstrates improved responses to vascular-targeted therapies. However, the molecular signatures that define VETC-positive HCC remain elusive. This study employed spatial transcriptomics and single-cell RNA sequencing to characterize the molecular landscape of VETC-positive HCC and identify candidate biomarkers.</p><p><strong>Methods: </strong>Using GeoMx Digital Spatial Profiling, we analyzed tumor and adjacent liver tissues from 24 HCC patients, focusing on VETC-positive, VETC-negative, or non-neoplastic liver regions. Differential gene expression and pathway enrichment analyses were performed. Candidate genes were further evaluated using immunohistochemistry, The Cancer Genome Atlas (TCGA) dataset, and single-cell RNA sequencing.</p><p><strong>Results: </strong>Spatial transcriptomic analysis identified 39 genes upregulated in VETC-positive regions, with enrichment of angiogenesis, WNT/β-catenin, Hedgehog, and p53 signaling, epithelial-mesenchymal transition, and fatty acid metabolism pathways, and suppression of immune-related pathways. Among these, LAMTOR2, DPP4, ZNHIT1, and MLXIPL were consistently upregulated in VETC-positive regions compared to both VETC-negative and normal liver regions. LAMTOR2 demonstrated tumor-specific localization in TCGA dataset. Immunohistochemistry confirmed that peripheral accentuation pattern of LAMTOR2 expression was restricted to tumor cells and strongly correlated with RNA expression and VETC positivity. Single-cell RNA sequencing further revealed LAMTOR2 upregulation in malignant hepatocytes, particularly within VETC-high subpopulations enriched for lipid degradation, fatty acid oxidation, and detoxification pathways.</p><p><strong>Conclusion: </strong>VETC-positive HCC exhibits a distinct transcriptomic and metabolic profile. LAMTOR2, which is consistently upregulated in VETC-positive HCCs, may contribute to angiogenic and metabolic reprogramming, offering potential implications for therapeutic stratification in HCC.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1150-1161"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148328788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of radiation therapy plus targeted therapy with or without immunotherapy for lymph node metastases in hepatocellular carcinoma. 放疗加靶向治疗伴或不伴免疫治疗治疗肝细胞癌淋巴结转移的疗效。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-01 Epub Date: 2026-06-26 DOI: 10.1007/s12072-026-11109-0
Li Zhang, Maopei Chen, Jing Sun, Zhaochong Zeng, Yang Zhang, Ping Yang, Yixing Chen, Shisuo Du
{"title":"Efficacy of radiation therapy plus targeted therapy with or without immunotherapy for lymph node metastases in hepatocellular carcinoma.","authors":"Li Zhang, Maopei Chen, Jing Sun, Zhaochong Zeng, Yang Zhang, Ping Yang, Yixing Chen, Shisuo Du","doi":"10.1007/s12072-026-11109-0","DOIUrl":"10.1007/s12072-026-11109-0","url":null,"abstract":"<p><strong>Background and aims: </strong>This study aimed to investigate the efficacy of radiation therapy and targeted therapy combined with or without immunotherapy for hepatocellular carcinoma (HCC) patients with lymph node metastases (LNM).</p><p><strong>Methods: </strong>A total of 132 HCC patients with LNM were enrolled in this study. Propensity score matching (PSM) and stabilized inverse probability of treatment weighting (sIPTW) were used to balance baseline variables between groups. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and clinical safety were compared between the two treatment arms.</p><p><strong>Results: </strong>There were 61 patients in radiotherapy plus targeted therapy (RT) group, and 71 patients in radiation therapy, targeted therapy combined with immunotherapy (RTI) group. In the overall cohort, the median OS was 12.8 months in the RT group and 18.8 months in the RTI group (p = 0.003). Multivariate analysis identified that tumor thrombus status, distant metastasis, lymph node (LN) number, LN size and immunotherapy were independent prognostic factors for survival. Median PFS was 7.0 months in the RT group and 11.9 months in the RTI group (p = 0.001). The ORRs were 70.5% for the RT group and 85.9% for the RTI group in the total cohort (p = 0.031). After PSM and IPTW adjustment, ORR remained significantly higher in the RTI group (PSM: 88.9% vs. 68.9%, p = 0.020; IPTW: 86.8% vs. 71.5%, p = 0.033). The incidence of treatment-related adverse events was similar in both groups.</p><p><strong>Conclusions: </strong>The findings of this study suggest that RTI provides superior treatment responses and survival outcomes compared to RT in HCC patients with LNM, while maintaining a comparable safety profile.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1177-1192"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148337783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on "Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study". 评论“阿特唑单抗和贝伐单抗联合或不联合TACE作为一线治疗不可切除HCC的疗效和安全性:一项多中心队列研究”。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-01 Epub Date: 2026-01-03 DOI: 10.1007/s12072-025-10970-9
Huikang Wang, Xinjun Xu, Xicheng Song, Yu Zhang
{"title":"Comment on \"Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study\".","authors":"Huikang Wang, Xinjun Xu, Xicheng Song, Yu Zhang","doi":"10.1007/s12072-025-10970-9","DOIUrl":"10.1007/s12072-025-10970-9","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1193-1195"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145892322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to letters to editor "Next-Step Paradigms for Hepatitis B Functional Cure: Insights from the Anchor Combination Therapy Trial" and "Critical Appraisal of the Anchor RCT on Entecavir, Peginterferon Alfa-2b, and GM-CSF Combination Therapy". 回复给编辑的信。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-01 Epub Date: 2026-02-17 DOI: 10.1007/s12072-026-11055-x
Di Wu, Da Huang, Weiming Yan, Qin Ning
{"title":"Response to letters to editor \"Next-Step Paradigms for Hepatitis B Functional Cure: Insights from the Anchor Combination Therapy Trial\" and \"Critical Appraisal of the Anchor RCT on Entecavir, Peginterferon Alfa-2b, and GM-CSF Combination Therapy\".","authors":"Di Wu, Da Huang, Weiming Yan, Qin Ning","doi":"10.1007/s12072-026-11055-x","DOIUrl":"10.1007/s12072-026-11055-x","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1259-1260"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Methodological considerations for interpreting associations between fatty liver disease definitions and cardiac diastolic function. 解释脂肪肝疾病定义与心脏舒张功能之间关系的方法学考虑。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-01 Epub Date: 2025-12-04 DOI: 10.1007/s12072-025-10982-5
Hui-Chin Chang, Shuo-Yan Gau
{"title":"Methodological considerations for interpreting associations between fatty liver disease definitions and cardiac diastolic function.","authors":"Hui-Chin Chang, Shuo-Yan Gau","doi":"10.1007/s12072-025-10982-5","DOIUrl":"10.1007/s12072-025-10982-5","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1233-1234"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145668209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refining the assessment of cardiac dysfunction in MAFLD and MASLD: a commentary on study limitations. 完善对MAFLD和MASLD心功能障碍的评估:对研究局限性的评论。
IF 7.8 2区 医学
Hepatology International Pub Date : 2026-08-01 Epub Date: 2025-12-08 DOI: 10.1007/s12072-025-10990-5
Zhuo Liu, Zhihui Xu, Nan Wang
{"title":"Refining the assessment of cardiac dysfunction in MAFLD and MASLD: a commentary on study limitations.","authors":"Zhuo Liu, Zhihui Xu, Nan Wang","doi":"10.1007/s12072-025-10990-5","DOIUrl":"10.1007/s12072-025-10990-5","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1227-1228"},"PeriodicalIF":7.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145700717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书